Mechanism, Dosing & Storage: The Key Differences Explained
Which Is Best Wegovy or Mounjaro: Understanding the Core Mechanisms
The fundamental difference when deciding which is best Wegovy or Mounjaro lies in their mechanisms of action. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone, reducing appetite and promoting satiety after smaller meals. Mounjaro, containing tirzepatide, is a dual-action treatment targeting both GIP and GLP-1 receptors, potentially offering enhanced glucose control alongside appetite suppression.
Both prescription-only medicines work on brain appetite centres but through different pathways. Wegovy's single-hormone approach has extensive clinical data spanning over five years, while Mounjaro's dual-receptor mechanism represents newer therapeutic innovation. Your prescriber can evaluate which mechanism aligns with your metabolic profile, existing health conditions, and weight management objectives. Neither treatment works in isolation—both require commitment to reduced-calorie diet and increased physical activity for optimal results.
Wegovy vs Mounjaro Pricing: Complete UK Cost Comparison
When comparing which is best Wegovy or Mounjaro from a cost perspective, both treatments follow different pricing structures. Wegovy starts at £79.99 for the 0.25mg starter dose, progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to £209.99 for the 2.4mg maintenance dose. New customers apply code FIRST40 at checkout, while returning customers use DOSE25. Bundle options like the Intro Trio (0.25mg, 0.5mg, 1mg) cost £299.99, providing three months of step-up dosing.
Mounjaro pricing follows its own escalation schedule with six dose levels from 2.5mg to 15mg. The choice between treatments shouldn't be based solely on initial cost, as both require long-term commitment for sustained results. EverydayMeds stocks both options, allowing your prescriber to recommend based on clinical suitability rather than availability constraints. Our GPhC-registered pharmacy (#9012878) ensures consistent supply chains for whichever treatment proves most appropriate for your circumstances.
Clinical Evidence: STEP vs SURMOUNT Trial Data
Clinical evidence helps determine which is best Wegovy or Mounjaro for different patient populations. Wegovy's STEP trial programme, including the landmark STEP 1 study (Wilding et al., NEJM, 2021), demonstrated that patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks. The recent SELECT trial showed a 20% reduction in major cardiovascular events, expanding Wegovy's clinical profile beyond weight management.
Mounjaro's SURMOUNT trials evaluated tirzepatide in weight management, with participants achieving notable results when combined with lifestyle interventions. However, directly comparing trial percentages isn't meaningful due to different study designs, participant populations, and endpoints. Your prescriber will consider your individual health profile, comorbidities, and treatment goals rather than relying solely on aggregate trial data to determine suitability.
How Wegovy Works: GLP-1 Receptor Mechanism Explained
Understanding how Wegovy works clarifies why it may be optimal when considering which is best Wegovy or Mounjaro for certain individuals. Wegovy mimics GLP-1 (glucagon-like peptide-1), a hormone naturally released by your intestines after eating. This hormone signals your brain's appetite centres to reduce hunger and increase feelings of fullness after smaller portions. The once-weekly FlexTouch pen delivers consistent semaglutide levels, maintaining appetite suppression throughout the week. Unlike some weight management approaches, Wegovy works with your body's existing hormonal pathways rather than stimulating metabolism artificially. The treatment requires dose escalation from 0.25mg to 2.4mg over 16 weeks, allowing your body to adapt gradually while minimising potential side effects.
Streamlined Ordering Process for Both Treatments
EverydayMeds simplifies the decision of which is best Wegovy or Mounjaro by offering both through the same streamlined process. Complete our 3-minute online clinical assessment covering medical history, current medications, weight management goals, and lifestyle factors. Our prescribers review applications within 3 working days (24 hours for express service), evaluating suitability for either treatment based on MHRA licensing criteria and NICE guidelines. Once approved, your chosen treatment ships via next-day delivery using temperature-controlled cold-chain logistics to maintain medication integrity. Our pharmacy team coordinates with your prescriber if dose adjustments or treatment switches become necessary. The entire process operates through our GPhC-registered facility (#9012878), ensuring professional oversight at every stage.
Storage and Practical Considerations: Wegovy's Travel Advantage
Storage requirements significantly impact daily life when deciding which is best Wegovy or Mounjaro for frequent travellers or those with inconsistent fridge access. Wegovy pens remain stable for up to 6 weeks at room temperature below 30°C once removed from refrigeration, while Mounjaro requires return to refrigeration within 21 days. This makes Wegovy more suitable for extended travel, business trips, or situations where refrigeration isn't assured. Both treatments require storage between 2-8°C before first use and should never be frozen. The FlexTouch pen system is identical for both treatments, with clear dose windows and simple injection mechanisms. Dose escalation schedules differ: Wegovy follows a 5-dose progression over 16 weeks, while Mounjaro offers 6 dose levels with potentially different timing based on individual response.
Which Is Best Wegovy or Mounjaro: Personalised Treatment Selection
The question of which is best Wegovy or Mounjaro doesn't have a universal answer—it depends on your individual circumstances, health profile, and lifestyle requirements. Wegovy's established clinical track record and superior storage flexibility suit patients prioritising convenience and proven outcomes. Mounjaro's dual-receptor mechanism may benefit individuals with specific metabolic profiles or those who haven't achieved desired results with single-hormone treatments.
Your prescriber considers multiple factors: existing health conditions, medication interactions, injection preferences, travel requirements, and cost considerations. Some patients respond better to GLP-1-only treatments, while others benefit from dual GIP/GLP-1 receptor activation. EverydayMeds' advantage lies in offering both options with expert prescriber guidance, eliminating the need to choose based on availability constraints rather than clinical suitability.
Start Your Weight Management Journey Today
Don't let the decision between Wegovy and Mounjaro delay your weight management progress—EverydayMeds provides access to both treatments with professional prescriber support. New customers use code FIRST40 at checkout, while returning customers apply DOSE25 for discounted pricing. Our clinical team evaluates your individual circumstances to recommend the most appropriate treatment, whether that's Wegovy's proven single-hormone approach or Mounjaro's innovative dual-receptor mechanism. Visit our weight loss collection at https://everydaymeds.co.uk/collections/weight-loss to begin your clinical assessment. Both treatments represent significant advances in prescription weight management, and our prescribers ensure you receive the option best suited to your specific needs and goals.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
